Advertisement


Lisa A. Carey, MD, and Maki Tanioka, MD, on HER2+ Breast Cancer: Results From the CALGB 40601 Alliance Trial

2016 San Antonio Breast Cancer Symposium

Advertisement

Lisa A. Carey, MD, and Maki Tanioka, MD, both of the University of North Carolina, discuss study findings on weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (Abstract S3-05).



Related Videos

Breast Cancer

Eric P. Winer, MD: The McGuire Lecture

Eric P. Winer, MD, of the Dana-Farber Cancer Institute, summarizes his McGuire lecture on the past and future of breast cancer treatment.

Breast Cancer

Samuel Smith, PhD, on Tamoxifen Adherence: Results of the IBIS-1 Study

Samuel Smith, PhD, of Queen Mary University of London, discusses study findings on menopausal symptoms as predictors of long‐term adherence in an International breast cancer intervent...

Breast Cancer

Virginia G. Kaklamani, MD, DSc, on Early Breast Cancer: Year in Review

Virginia G. Kaklamani, MD, DSc, of The University of Texas Health Science Center, discusses new directions in prevention, early detection, and treatment of early-stage breast cancer, ...

Breast Cancer

S.P. Somashekhar, MBBS, MCh(Onco), on Watson for Oncology: A Validation Study for Breast Cancer

S.P. Somashekhar, MBBS, MCh(Onco), of the Manipal Comprehensive Cancer Centre, discusses a study to assess the performance of IBM's artificial intelligence platform in comparison to a...

Breast Cancer

Ruth O’Regan, MD, and Ann H. Partridge, MD, on The NRG Oncology/NSABP B-42, IDEAL, and DATA Studies

Ruth O’Regan, MD, of the University of Wisconsin, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss study findings from a session Dr. O’Regan mod...

Advertisement

Advertisement



Advertisement